ReviewEClinicalMedicine2024
Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL.
Review in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A European platform trial for major depressive disorder.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Design, simulate, refine: simulation-guided clinical trials for accelerated drug development.Nature reviews. Drug discovery · 2026Review
- A five-phase evaluation framework for diagnostic and predictive medical artificial intelligence.NPJ digital medicine · 2026Article
- Barriers and Facilitators to Intracerebral Haemorrhage Platform Trial Recruitment: A Survey of Stroke Clinicians.Cerebrovascular diseases (Basel, Switzerland) · 2026Article
- An umbrella protocol for the clinical evaluation of diagnostics in infectious disease.Bulletin of the World Health Organization · 2026Article
- Article
- On the Inclusion of Non-Concurrent Controls in Platform Trials With an Interim Analysis.Statistics in medicine · 2026Article
- Aggregating and analysing clinical trials data from multiple public registers using R package ctrdata.Research synthesis methods · 2026Review
- Context defines precision: rethinking KRAS inhibition in oncology.NPJ precision oncology · 2026Review
- Evolution of Clinical Trial Design in ADPKD.Kidney international reports · 2026Review
- The federated trials approach; an opportunity for global collaboration in health emergencies.EClinicalMedicine · 2026Review
- Drug Repurposing for Metabolic-Associated Fatty Liver Disease: Current Evidence, Challenges, and Future Perspectives.Drug design, development and therapy · 2026Review
- Logistical Challenges in Platform Randomized Trials - Operational Realities That Curb the Promise of Efficiency.Clinical epidemiology · 2026Article
- Promoting collaboration, harmonization and dissemination in depression research: the ECNP Depression Meta-Network.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2025Article
- Statistical Modeling to Adjust for Time Trends in Adaptive Platform Trials Utilizing Non-Concurrent Controls.Biometrical journal. Biometrische Zeitschrift · 2025Article
- Identification and Estimation of Causal Effects Using Non-Concurrent Controls in Platform Trials.Statistics in medicine · 2025Article
- A critical approach to research on perioperative pain management.British journal of anaesthesia · 2025Article
- Review article: Primer for clinical researchers on innovative trial designs for emergency medicine.Emergency medicine Australasia : EMA · 2025Review
- Early immune modulation in cerebral palsy medical management of cerebral palsy series.Pediatric research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platform trials bring the promise of making clinical research more efficient and more patient centric. While their use has become more widespread, including their prominent role during the COVID-19 pandemic response, broader adoption of platform trials has been limited by the lack of experience and tools to navigate the critical upfront planning required to launch such collaborative studies. The European Union-Patient-cEntric clinicAl tRial pLatform (EU-PEARL) initiative has produced new methodologies to expand the use of platform trials with an overarching infrastructure and services embedded into Integrated Research Platforms (IRPs), in collaboration with patient representatives and through consultation with U.S. Food and Drug Administration and European Medicines Agency stakeholders. In this narrative review, we discuss the outlook for platform trials in Europe, including challenges related to infrastructure, design, adaptations, data sharing and regulation. Documents derived from the EU-PEARL project, alongside a literature search including PubMed and relevant grey literature (e.g., guidance from regulatory agencies and health technology agencies) were used as sources for a multi-stage collaborative process through which the 10 more important points based on lessons drawn from the EU-PEARL project were developed and summarised as guidance for the setup of platform trials. We conclude that early involvement of critical stakeholder such as regulatory agencies or patients are critical steps in the implementation and later acceptance of platform trials. Addressing these gaps will be critical for attaining the full potential of platform trials for patients. Funding: Innovative Medicines Initiative 2 Joint Undertaking with support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.